Abstract:SESSION TITLE: Asthma IV SESSION TYPE: Original Investigation Poster PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM PURPOSE: Eosinophilic airway inflammation can predict the exacerbation of asthma, and we can improve the management of asthma by monitoring the eosinophilic airway inflammation. Although induced sputum and sputum eosinophil count is the gold standard test for diagnosing eosinophilic asthma, a more accessible and receptive method is needed for clinical practice. Type 2 innate lymphoid cells (ILC2) have recently been proposed to play a crucial role in eosinophilic inflammation and have been identified in peripheral blood from patients with asthma. We sought to identify simple and feasible biomarkers which can predict eosinophilic airway inflammation in asthmatic patients. METHODS: Sputum was induced for the assessment of eosinophils in 150 asthmatic patients. In parallel, the proportion of ILC2s of peripheral blood lymphocytes (%ILC2), blood eosinophil counts, total immunoglobulin E (IgE), fractional exhaled nitric oxide (FeNO) and lung function tests were measured. RESULTS: 126 patients finished sputum induction and produced adequate sputum. The ILC2 level was significantly increased in eosinophilic asthmatic patients compared with non-eosinophilic asthmatic patients (0.117±0.090versus0.035±0.021, p<0.001). A multiple regression model, including age, sex, BMI, blood eosinophil counts, FeNO, IgE and %ILC2, showed that %ILC2, blood eosinophil counts and FeNO were correlative factors of sputum eosinophil counts (p<0.001, p=0.037, p<0.001, respectively) and %ILC2 was the most significant subset of airway eosinophilic inflammation (Estimate=11.385). A receiver operating characteristic (ROC) analysis showed a sensitivity of 67.7% and a specificity of 95.3% for %ILC2 of 0.076 to distinguish eosinophilic asthmatic patients from non-eosinophilic asthmatic patients. CONCLUSIONS: ILC2 is a surrogate marker of airway eosinophilic inflammation in patients with mild to moderate asthma and has great potential advantages for selecting the asthmatic patients most likely to benefit from therapeutics targeting Th2 inflammation. CLINICAL IMPLICATIONS: Our study demonstrates that blood ILC2 can reflect airway eosinophilic inflammation in mild to moderate asthmatic patients, and this provides a new insight for the biomarker of eosinophilic asthma. The level of ILC2 might help identify and select those patients most likely to respond to these biological therapeutics. DISCLOSURE: The following authors have nothing to disclose: Liang Dong No Product/Research Disclosure Information

Pathological ILC2 in Peripheral Blood Acts As an Indicator for the Assessment of Asthma Control in Clinics

Peripheral Pathological ILC2: an Inflammatory Indicator for the Assessment of Asthma Control in Clinics

IL-13+ Type 2 Innate Lymphoid Cells Correlate with Asthma Control Status and Treatment Response.

Type 2 Innate Lymphoid Cells: A Novel Biomarker of Eosinophilic Airway Inflammation in Patients with Mild to Moderate Asthma

Increased Group 2 Innate Lymphoid Cells Are Correlated with Eosinophilic Granulocytes in Patients with Allergic Airway Inflammation

Increased Expression of Type 2 Innate Lymphoid Cells in Pediatric Patients with Allergic Rhinitis.

ILC2s: Unraveling the Innate Immune Orchestrators in Allergic Inflammation

Innate-like Lymphocytes and Innate Lymphoid Cells in Asthma

Interleukin-2 family cytokines IL-9 and IL-21 differentially regulate innate and adaptive type 2 immunity in asthma

Interleukin-31 Expression and Relation to Disease Severity in Human Asthma.

Clinical Significance of Combined Detection of CCL22 and IL‐1 as Potential New Bronchial Inflammatory Mediators in Children's Asthma

Decreased Circulating Interleukin-35 Levels Are Related to Interleukin-4-Producing CD8+ T Cells in Patients with Allergic Asthma.

Modulating ILC2 function for treatment of type 2 airway diseases

A potential immunopathogenic role for reduced IL-35 expression in allergic asthma

Increased Innate Type 2 Immune Response in House Dust Mite-Allergic Patients with Allergic Rhinitis

The Role of Peripheral Type 2 Innate Lymphoid Cells in Bronchiolitis

Effect of Interleukin-33 on Th1/Th2 Cytokine Ratio in Peripheral Lymphocytes in Asthmatic Mice.

The absence of IL-9 reduces allergic airway inflammation by reducing ILC2, Th2 and mast cells in murine model of asthma

ILC2s Induce Adaptive Th2-Type Immunity in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Blocking CD226 regulates ILC2 effector function and alleviates airway hyperreactivity

Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling